• Instil Bio reported a net loss of USD 4.2 million, or USD 0.62 per share, for first-quarter 2026, narrowing from a loss of USD 28.2 million, or USD 4.32 per share, a year earlier.
• Operating loss tightened to USD 7.01 million as total operating expenses fell to USD 7.01 million.
• R&D expense dropped to USD 669,000, while general and administrative costs declined to USD 5.35 million.
• Cash, cash equivalents, restricted cash and marketable securities totaled USD 74.7 million at March 31, with runway expected to fund current operating plan beyond 2027.
• Management said it is evaluating potential acquisitions and in-licensing to access novel therapeutic candidates as it refines strategy for next growth phase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Instil Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150700PRIMZONEFULLFEED9720858) on May 15, 2026, and is solely responsible for the information contained therein.